Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy induced anaemia

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 781-787

  Barosi, G ^a   Marchetti, M ^a   Liberato, N L ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chemotherapy induced anaemia; Cisplatin containing chemotherapy; Cost effectiveness analysis; Decision analysis; Recombinant human erythropoietin

Indexed keywords

CISPLATIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD DISEASE; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE TRANSFUSION; HUMAN; HYPERTENSION; INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; THROMBOSIS;

EID: 0031713770     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.579     Document Type: Article

References (39)

1. Abels RI (1992) Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 87 (suppl. 1): 4-11
2. Abels RI (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A (suppl. 2): S2-S8
3. Alter MJ (1988) Transfusion-associated non-A, non-B hepatitis: the first decade. In Viral Hepatitis and Liver Disease, Zuckerman AJ (ed), pp 537-542. Alan R. Liss: New York
4. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander J, Ya Hu P, Miller JK, Gerber MA, Sampliner RE, Meeks EL and Beach MJ for the Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team (1992) The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327: 1899-1905
5. Barosi G and Liberato NL (1996) The cost-effectiveness of rhEPO use in anemia of cancer. In rhErythropoietin in Cancer Supportive Treatment, Smyth JF, Boogaerts MA and Ehmer BR-M (eds), pp. 45-57. M Dekker: New York
6. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsu PG and Littenberg B (1993) The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 33: 544-551
7. Blajchman MA, Bull SB and Feinman SV for the Canadian Post-Transfusion Hepatitis Prevention Study Group (1995) Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Lancet 345: 21-25
8. Cascinu S, Fedeli A, Del Ferro A, Luzi Fedeli S and Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia. A randomized double blind trial with placebo. J Clin Oncol 12: 1058-1062
9. Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones E, Keler AM, Kugler JW, Nichols CR, Salmon SE, Silver RT, Storniolo AM, Wampler GL, Dooley CM, Larholt KM, Nelson RA and Abels RJ (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801-806
10. Cazzola M, Messinger M, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jarger G, LeMevel A, Najman A, Silingardi V, Spriano M, Van Hoof A and Ehmer B (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446-4453
11. De Campos E, Radford J, Steward W, Milroy R, Dougal M, Sweindell R, Testa N and Thatcher N (1995) Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 3: 1623-1631
12. Del Mastro L, Garrone O, Sertoli MR, Canavese G, Catturich G, Catturich A, Guenzi M, Rosso R and Venturini M (1994) A pilot study of accelerated cyclophosphamide, epirubicin and 5-flourouracil plus granulocyte-colony stimulating factor and adjuvant therapy in early breast cancer. Eur J Cancer 30A: 606-610
13. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M and Rosso R (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715-2721
14. Dodd RY (1992) The risk of transfusion-transmitted infection. N Engl J Med 327: 419-421
15. Donahue JG, Munoz A, Ness PM, Brown DE, Yawn DH, McAllister Jr HA, Reitz BA and Nerlson KE (1992) The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327: 369-373
16. Etchason J, Petz L, Keeler E, Calhoun L, Klenman S, Snider C, Fink A and Brook R (1995) The cost-effectiveness of preoperative autologous blood donation. N Engl J Med 332: 719-724
17. Finelli C, Cavo M, Visani G, Bonelli MA, Gamberi B, Fogli M, Cenacci A, Tosi P, Bertelletti D, Villa R and Tura S (1993) Recombinant human erythropoietin in lymphoproliferative disorders. In Disorders of Erythropoiesis: Therapeutical Implications, Grossi A, Vannucchi AM and Rossi Ferrini P (eds), pp. 35-39. Wichtig Editor: Milano
18. Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G and Kyle RA (1995) Epoetin alpha for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155: 2069-2074
19. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian and Vadhan-Raj S for the Procrit Study Group (1997) Impact of therapy with epoetin alpha on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234
20. Henry DH and Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia. Results of double-blind and open-label follow-up studies. Semin Oncol 21: 21-28
21. Koretz RL, Stone O, Mousa M and Gitnick GL (1985) Non-A, Non-B post-transfusion hepatitis - a decade later. Gastroenterology 88: 1251-1254
22. Koretz RL, Abbey H, Coleman E and Gitnick GL (1993) Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 119: 110-115
23. Lackritz EM, Satten GA, Aberlie-Grasse J, Dodd RT, Raimondi VP, Janssen RS, Lewis FWF, Notari IV EP and Petersen LR (1995) Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 333: 1721-1725
24. Leese B, Hutton J and Maynard A (1992) A comparison of the costs and benefits of recombinant human erythropoietin (Epoietin) in the treatment of chronic renal failure in 5 European countries. PharmacoEconomics 1: 346-356
25. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H and Schuster J (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84: 1056-1063
26. Maynard A (1991) Developing the health care market. Economic J 101: 1277-1286
27. Mohandas K and Aledort L (1995) Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 35: 427-4311
28. Nicholls AJ (1992) Enhanced quality of life in dialysis patients treated with erythropoietin: are the benefits worth the cost? Erythropoietin 3: 46-49
29. Oesterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jaeger G, Najman A and Peest D for the European Study Group of Erythropoietin (Epoietin Beta) treatment in Multiple Myeloma and non-Hodgkin's Lymphoma (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 87: 2675-2682
30. Schreiber GB, Busch MP, Kleinman SH and Korelitz JJ for the Retrovirus Epidemiology Donor Study (1996) The risk of transfusion-transmitted viral infections. N Engl J Med 334: 1685-1690
31. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnbick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG and the National Heart, Lung and Blood Institute Study group (1992) Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327: 1906-1911
32. Sheffield RE, Sullivan SD, Saltiel E and Nishimura L (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31: 15-22
33. Sheingold S, Churchill D, Muirhead N, Laupacis A, Labelle R and Goeree R (1992) The impact of recombinant human erythropoietin on medical care costs for haemodialysis patients in Canada. Soc Sci Med 34: 983-991
34. Task Force on Principles for Fconomic Analysis of Health Care Technology (1995) Economic analysis of health care technology. A report on principles. Ann Intern Med 122: 61-70
35. ten Bokkel-Huinink (1996) Controlled multicenter study of the influence of two different dosages of subcutaneous rhEPO on the development of anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based combination chemotherapy. In rhErythropoietin in Cancer Supportive Treatment, Smyth JF, Boogaerts MA and Ehmer BR-M (eds), pp. 99-112. M Dekker: New York
36. Tony MJ, El-Farra NS, Reikes AR and Co RL (1995) Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332: 1463-1446
37. Tretiak R, Laupacis A, Rivière M, McKerracher K, Souetre E and the Canadian Cost of Transfusion Study Group (1996) Cost of allogeneic and autologous blood transfusion in Canada. Can Med Assoc J 154: 1501-1508
38. Wong JB, Koff RS, Tinè F and Pauker SG (1995) Cost-effectiveness of interferon-α2b treatment for hepatitis B and antigen-positive chronic hepatitis B. Ann Intern Med 122: 664-675
39. Wurnig C, Windhager R, Schwameis E, Kotz A, Zoubek A, Stockenhuber F and Kurz RW (1996) Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind randomized, phase III study). Transfusion 36: 155-159